 BOSTON--BUSINESS WIRE--AVEO Oncology Nasdaq: AVEO today announced that the U.S. Food and Drug Administration FDA has approved FOTIVDA tivozanib for the treatment of adults with relapsed or refractory advanced renal cell carcinoma RCC who have received two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth factor VEGF tyrosine kinase inhibitor TKI. Todays approval of FOTIVDA provides a new tool for treating patients with kidney canc 